



Patent  
HDAC-5005-U

*ITW*

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of:

Jerome C. Bressi et al.

Serial No.: 10/803,344

Filed: March 17, 2004

For: HISTONE DEACETYLASE  
INHIBITORS

)  
) Group Art Unit: 1626

)  
) Examiner: Deborah C. Lambkin

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO-1449, and copies of the non-US patent references are included for the Examiner's convenience.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicants as such.

**CERTIFICATE OF HAND DELIVERY**

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being delivered via hand delivery to the Commissioner for Patents, Randolph Building, 401 Dulany Street, Alexandria, Virginia 22314.

*John Semiklose*  
Name of Person Delivering Paper

*John Semiklose*  
Signature of Person Delivering Paper

*July 14, 2006*  
Date of Deposit

**INFORMATION DISCLOSURE STATEMENT FILING PROVISION:**

☒ This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution application filed under § 1.53(d); or (2) within three months of entry of the national stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.

☒ However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR § 1.17(p) to the deposit account referenced below.

☐ However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and a statement under 37 CFR § 1.97(e) is included below, thus no fee is required.

☐ This IDS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office action on the merits, but before a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311.

☐ The fee due under 37 CFR § 1.17(p) is submitted herewith.

☐ A statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the event that this IDS is not received before a Final Action or a Notice of Allowance, then Applicant respectfully requests that the Office consider the filing of these papers to be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.

☐ This IDS is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311, but before payment of the issue fee. A statement under 37 CFR § 1.97(e) is included below. The fee due under 37 CFR § 1.17(p) is submitted herewith.

**STATEMENT UNDER 37 CFR § 1.97(e):**

☐ Each item contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.

☐ No item contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing

this statement after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this IDS.

**PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:**


- ☐ A check in the amount of \_\_\_\_\_ is enclosed for the above fee(s).  
☐ Please charge to Deposit Account No. **50-2256** for the above fee(s).

Although Applicants do not believe any fees are required, the Commissioner is authorized to charge any fees required by the filing of these papers to Takeda's Deposit Account No. **50-2256**.


Respectfully submitted,

TAKEDA SAN DIEGO, INC.

Dated: July 13, 2006

By:   
Mitchell R. Brustein  
Reg. No. 38,394

Customer No. **32793**  
Takeda San Diego, Inc.  
10410 Science Center Drive  
San Diego, CA 92121  
Tel: (858) 622-8528  
Fax: (858) 550-0992



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/803,344		
		Filing Date	March 17, 2004		
		First Named Inventor	Jerome C. Bressi		
		Group Art Unit	1626		
		Examiner Name	Deborah C. Lambkin		
Sheet	1	of	2	Attorney Docket Number	HDAC-5005-U

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date/ Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	AA	US 5,977,108	11/2/1999	Kouichi Kikuchi et al.	
	AB	US 6,099,851	8/8/2000	Kenneth M. Weisman et al.	
	AC	US 6,541,661	4/1/2003	Daniel Delorme et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	AD	EP 0 354 549 A2	2/14/1990	Konica Corporation		
	AE	EP 0 378 991 A1	7/25/1990	Ciba-Geigy AG		
	AF	JP 03 289654	12/19/1991	Konica Corporation		
	AG	EP 0 847 992 A1	6/17/1992	Mitsui Chemicals, Inc.		
	AH	EP 0570594 A	11/24/1993	SHIONOGI & CO., LTD.		
	AI	WO 97/29776 A1	8/21/1997	G.D. Searle & Co.		
	AJ	JP 11 095383	4/9/1999	Konica Corporation		
	AK	WO 01/70675	9/27/2001	METHYLGENE, INC.		
	AL	WO 02/26696	4/4/2002	PROLIFIX LIMITED		
	AM	WO 02/46129 A2	6/13/2002	Abbott Laboratories		
	AN	WO 03/024448 A2 & A3	3/27/2003	Methylgene, Inc.		
	AO	WO 03/039599 A1	5/15/2003	Novartis AG		
	AP	WO 03/066579 A2	8/14/2003	Axys Pharmaceuticals		
	AQ	WO 2004/046094	6/3/2004	Queen Mary & Westfield College		
	AR	WO 2005/019174	3/3/2005	Axys Pharmaceuticals, Inc.		
	AS	WO 2005/040161	5/6/2005	S*Bio PTE		
	AT	WO 2005/040101	5/6/2005	S*Bio PTE		
	AU	WO 2005/073180	8/11/2005	JKUREHA CHEMICAL INDUSTRY COMPANY, LIMITED		
	AV	EP 0 847 992 A1	6/17/1992	Mitsui Chemicals, Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/803,344
				Filing Date	March 17, 2004
				First Named Inventor	Jerome C. Bressi
				Group Art Unit	1626
				Examiner Name	Deborah C. Lambkin
Sheet	2	of	2	Attorney Docket Number	HDAC-5005-U


OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AW	Sasho, Setsuya et al. "Preparation and formulation of thiazole derivatives as cell adhesion inhibitors" Jpn. Kokai Tokkyo Koho, 42 pp. CA 127:17674 (1997)	
	AX	Wood, Warren J.L. et al. "Substrate activity screening: A fragment-based method for the rapid identification of nonpeptidic protease inhibitors" Journal of the American Chemical Society, (2005), 127(44), 15521-15527 143:452160	
	AY	Dai Yujia et al. "Indole amide hydroxamic acids as potent inhibitors of histone deacetylases." BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 13, no. 11, 2 June 2003 (2003-06-02), pages 1897-1901, XP002331281 ISSN: 0960-894X abstract; figures 1,2; tables 1-4	
	AZ	DATABASE BEILSTEIN INSTITUT ZUR FORDERUNG DER WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; 2 December 1991 (12/2/1991), XP002331282 Database accession no. 4311238 abstract	
	BA	DATABASE BEILSTEIN INSTITUT ZUR FORDERUNG DER WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; 2 December 1991 (12/2/1991), XP002331283 Database accession no. 5815061 abstract	
	BB	DATABASE BEILSTEIN INSTITUT ZUR FORDERUNG DER WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; 2 December 1991 (12/2/1991), XP002331284 Database accession no. 7765459 abstract	
	BC	DATABASE CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2002 XP002325919 Database accession no. AN:2002:217200	
	BD	Lam, Patrick Y.S. et al. "Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants" Journal of Medical Chemistry (2003), 46 (21) 4405-4418, CASREACT 140; 12453	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

**Complete if Known**

Application Number	10/803,344
Filing Date	March 17, 2004
First Named Inventor	Jerome C. Bressi
Group Art Unit	1626
Examiner Name	Deborah C. Lambkin
Attorney Docket Number	HDAC-5005-U

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date/ Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	AA	US 5,977,108	11/2/1999	Kouichi Kikuchi et al.	
	AB	US 6,099,851	8/8/2000	Kenneth M. Weisman et al.	
	AC	US 6,541,661	4/1/2003	Daniel Delorme et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	AD	EP 0 354 549 A2	2/14/1990	Konica Corporation		
	AE	EP 0 378 991 A1	7/25/1990	Ciba-Geigy AG		
	AF	JP 03 289654	12/19/1991	Konica Corporation		
	AG	EP 0 847 992 A1	6/17/1992	Mitsui Chemicals, Inc.		
	AH	EP 0570594 A	11/24/1993	SHIONOGI & CO., LTD.		
	AI	WO 97/29776 A1	8/21/1997	G.D. Searle & Co.		
	AJ	JP 11 095383	4/9/1999	Konica Corporation		
	AK	WO 01/70675	9/27/2001	METHYLGENE, INC.		
	AL	WO 02/26696	4/4/2002	PROLIFIX LIMITED		
	AM	WO 02/46129 A2	6/13/2002	Abbott Laboratories		
	AN	WO 03/024448 A2 & A3	3/27/2003	Methylgene, Inc.		
	AO	WO 03/039599 A1	5/15/2003	Novartis AG		
	AP	WO 03/066579 A2	8/14/2003	Axys Pharmaceuticals		
	AQ	WO 2004/046094	6/3/2004	Queen Mary & Westfield College		
	AR	WO 2005/019174	3/3/2005	Axys Pharmaceuticals, Inc.		
	AS	WO 2005/040161	5/6/2005	S*Bio PTE		
	AT	WO 2005/040101	5/6/2005	S*Bio PTE		
	AU	WO 2005/073180	8/11/2005	JKUREHA CHEMICAL INDUSTRY COMPANY, LIMITED		
	AV	EP 0 847 992 A1	6/17/1992	Mitsui Chemicals, Inc.		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/803,344
				Filing Date	March 17, 2004
				First Named Inventor	Jerome C. Bressi
				Group Art Unit	1626
				Examiner Name	Deborah C. Lambkin
Sheet	1	of	2	Attorney Docket Number	HDAC-5005-U

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date/ Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	AA	US 5,977,108	11/2/1999	Kouchi Kikuchi et al.	
	AB	US 6,099,851	8/8/2000	Kenneth M. Weisman et al.	
	AC	US 6,541,661	4/1/2003	Daniel Delorme et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	AD	EP 0 354 549 A2	2/14/1990	Konica Corporation		
	AE	EP 0 378 991 A1	7/25/1990	Ciba-Geigy AG		
	AF	JP 03 289654	12/19/1991	Konica Corporation		
	AG	EP 0 847 992 A1	6/17/1992	Mitsui Chemicals, Inc.		
	AH	EP 0570594 A	11/24/1993	SHIONOGI & CO., LTD.		
	AI	WO 97/29776 A1	8/21/1997	G.D. Searle & Co.		
	AJ	JP 11 095383	4/9/1999	Konica Corporation		
	AK	WO 01/70675	9/27/2001	METHYLGENE, INC.		
	AL	WO 02/26696	4/4/2002	PROLIFIX LIMITED		
	AM	WO 02/46129 A2	6/13/2002	Abbott Laboratories		
	AN	WO 03/024448 A2 & A3	3/27/2003	Methylgene, Inc.		
	AO	WO 03/039599 A1	5/15/2003	Novartis AG		
	AP	WO 03/066579 A2	8/14/2003	Axys Pharmaceuticals		
	AQ	WO 2004/046094	6/3/2004	Queen Mary & Westfield College		
	AR	WO 2005/019174	3/3/2005	Axys Pharmaceuticals, Inc.		
	AS	WO 2005/040161	5/6/2005	S*Bio PTE		
	AT	WO 2005/040101	5/6/2005	S*Bio PTE		
	AU	WO 2005/073180	8/11/2005	JKUREHA CHEMICAL INDUSTRY COMPANY, LIMITED		
	AV	EP 0 847 992 A1	6/17/1992	Mitsui Chemicals, Inc.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/803,344
				Filing Date	March 17, 2004
				First Named Inventor	Jerome C. Bressi
				Group Art Unit	1626
				Examiner Name	Deborah C. Lambkin
Sheet	1	of	2	Attorney Docket Number	HDAC-5005-U

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date/ Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	AA	US 5,977,108	11/2/1999	Kouichi Kikuchi et al.	
	AB	US 6,099,851	8/8/2000	Kenneth M. Weisman et al.	
	AC	US 6,541,661	4/1/2003	Daniel Delorme et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	AD	EP 0 354 549 A2	2/14/1990	Konica Corporation		
	AE	EP 0 378 991 A1	7/25/1990	Ciba-Geigy AG		
	AF	JP 03 289654	12/19/1991	Konica Corporation		
	AG	EP 0 847 992 A1	6/17/1992	Mitsui Chemicals, Inc.		
	AH	EP 0570594 A	11/24/1993	SHIONOGI & CO., LTD.		
	AI	WO 97/29776 A1	8/21/1997	G.D. Searle & Co.		
	AJ	JP 11 095383	4/9/1999	Konica Corporation		
	AK	WO 01/70675	9/27/2001	METHYLGENE, INC.		
	AL	WO 02/26696	4/4/2002	PROLIFIX LIMITED		
	AM	WO 02/46129 A2	6/13/2002	Abbott Laboratories		
	AN	WO 03/024448 A2 & A3	3/27/2003	Methylgene, Inc.		
	AO	WO 03/039599 A1	5/15/2003	Novartis AG		
	AP	WO 03/066579 A2	8/14/2003	Axys Pharmaceuticals		
	AQ	WO 2004/046094	6/3/2004	Queen Mary & Westfield College		
	AR	WO 2005/019174	3/3/2005	Axys Pharmaceuticals, Inc.		
	AS	WO 2005/040161	5/6/2005	S*Bio PTE		
	AT	WO 2005/040101	5/6/2005	S*Bio PTE		
	AU	WO 2005/073180	8/11/2005	JKUREHA CHEMICAL INDUSTRY COMPANY, LIMITED		
	AV	EP 0 847 992 A1	6/17/1992	Mitsui Chemicals, Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/803,344
				Filing Date	March 17, 2004
				First Named Inventor	Jerome C. Bressi
				Group Art Unit	1626
				Examiner Name	Deborah C. Lambkin
Sheet	2	of	2	Attorney Docket Number	HDAC-5005-U

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AW	Sasho, Setsuya et al. "Preparation and formulation of thiazole derivatives as cell adhesion inhibitors" Jpn. Kokai Tokkyo Koho, 42 pp. CA 127:17674 (1997)	
	AX	Wood, Warren J.L. et al. "Substrate activity screening: A fragment-based method for the rapid identification of nonpeptidic protease inhibitors" Journal of the American Chemical Society, (2005), 127(44), 15521-15527 143:452160	
	AY	Dai Yujia et al. "Indole amide hydroxamic acids as potent inhibitors of histone deacetylases." BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 13, no. 11, 2 June 2003 (2003-06-02), pages 1897-1901, XP002331281 ISSN: 0960-894X abstract; figures 1,2; tables 1-4	
	AZ	DATABASE BEILSTEIN INSTITUT ZUR FORDERUNG DER WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; 2 December 1991 (12/2/1991), XP002331282 Database accession no. 4311238 abstract	
	BA	DATABASE BEILSTEIN INSTITUT ZUR FORDERUNG DER WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; 2 December 1991 (12/2/1991), XP002331283 Database accession no. 5815061 abstract	
	BB	DATABASE BEILSTEIN INSTITUT ZUR FORDERUNG DER WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; 2 December 1991 (12/2/1991), XP002331284 Database accession no. 7765459 abstract	
	BC	DATABASE CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2002 XP002325919 Database accession no. AN:2002:217200	
	BD	Lam, Patrick Y.S. et al. "Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants" Journal of Medical Chemistry (2003), 46 (21) 4405-4418, CASREACT 140; 12453	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.